Department of Pathology, Microbiology, and Immunology



  Harold J. Helderman, M.D., FACP




Dept of Medicine

Dept. of Pathology, Microbiology and Immunology



Contact Information



Office Location:
MCN S-3305
Phone: 615-322-6976

E-mail:  hal.helderman@Vanderbilt.Edu


Campus Mail address:

Dept. of Medicine


MCN S-3301 (2372)


US Mailing Address:
Vanderbilt University School of Medicine
Department of Medicine


MCN S-3301

1161 21st Ave. S.
Nashville, TN 37232-2372







M.D., SUNY, Downstate
B.A., Rochester



Research Keywords





Research Description



Dr. Helderman is the Medical Director of the multi-organ, multi-disciplinary Vanderbilt Transplant Center. He attends on the renal transplant service managing in-patients with fresh renal transplants and problems of previously placed organs. He maintains two out-patient transplant clinics per week at Vanderbilt and a transplant clinic once a month at St. Thomas. His clinical research interests have involved the development of new immunosuppressive strategies, the pathogenesis and treatment of chronic rejection, the pathogenesis and management of medical complications of transplantation including infection, neoplasia, metabolic disorders including diabetes and bone disease, and cardiac disease. Dr. Helderman is nationally recognized as a leader in transplantation. He serves as the President of the American Society of Transplant Physicians, is on a national board of the United Network of Organ Sharing, represents transplantation on the Council of the American Kidney Societies. He is the Associate Editor of the American Journal of Kidney Disease and on the Editorial Board of multiple kidney and transplantation journals.

Research Interests

Dr. Helderman has been very involved in the basic investigation into the regulation and description of lymphocyte activation pathways with particular reference to growth factor and cytokine receptors on T-lymphocytes. Using the model of the nonconstitutive activation marker, the insulin receptor, Dr. Helderman has developed an understanding of antigen-driven activation signals for the synthesis of new immunomodulatory molecules. His laboratory has discovered a monokine which regulates early lymphocyte activation cytokine and growth factor genes called Monocyte Receptor Regulatory Factor (MRRF) and has purified this substance to homogeneity and sequenced it. More recently the research interests of Dr. Helderman have been involved in the clinical research arena studying several new immunosuppressive drugs including Deoxyspergualin, Neoral Cyclosporine, Sirolimus (Rapamycin), and polyclonal rabbit anti-thymocyte globulin. A recent NIH trial of steroid withdrawal in Mycophenolate treated renal transplant patients has been initiated by Dr. Helderman. Chronic rejection its pathogenesis and management is a major research interest of Dr. Helderman. A 5-year NIH funded multicenter trial on this topic has begun this year.






Giannico, GA, Arnold, S, Langone, A, Schaefer, H, Helderman, JH, Shaffer, D, Fogo, AB. Non-immunoglobulin A mesangial immune complex glomerulonephritis in kidney transplants. Hum Pathol, 46(10), 1521-8, 2015

Ahmed, F, Helderman, JH, Langone, A, Schaefer, H. Persistent shortness of breath in a kidney transplant recipient. Am J Transplant, 14(4), 974-6, 2014

Langone, AJ, Helderman, JH. Mammalian target of rapamycin inhibitors in organ transplantation: an unkept promise. Chest, 142(3), 734-7, 2012

Kasiske, BL, Israni, AK, Snyder, JJ, Camarena, A, , . Design considerations and feasibility for a clinical trial to examine coronary screening before kidney transplantation (COST). Am J Kidney Dis, 57(6), 908-16, 2011

Schaefer, HM, Helderman, JH. Contemporary dialysis: as good as transplantation. Nat Rev Nephrol, 6(1), 8-9, 2010

Schaefer, HM, Langone, A, Helderman, JH, Fogo, AB. Recurrent pauci-immune necrotizing crescentic glomerulonephritis in a kidney transplant patient. Am J Kidney Dis, 55(3), 604-8, 2010

Helderman, JH, Kang, N, Legorreta, AP, Chen, JY. Healthcare costs in renal transplant recipients using branded versus generic ciclosporin. Appl Health Econ Health Policy, 8(1), 61-8, 2010

Schaefer, HM, Helderman, JH. Allograft nephrectomy after transplant failure: should it be performed in all patients returning to dialysis. J Am Soc Nephrol, 21(2), 207-8, 2010

Giullian, JA, Helderman, JH. Do calcium channel blockers prevent delayed graft function after renal transplantation. Nat Clin Pract Nephrol, 4(4), 192-3, 2008

Gilmore, AS, Helderman, JH, Ricci, JF, Ryskina, KL, Feng, S, Kang, N, Legorreta, AP. Linking the US transplant registry to administrative claims data: expanding the potential of transplant research. Med Care, 45(6), 529-36, 2007

Schaefer, HM, Kizilisik, AT, Feurer, I, Nylander, WA, Langone, AJ, Helderman, JH, Shaffer, D. Short-term results under three different immunosuppressive regimens at one center. Transplant Proc, 38(10), 3466-7, 2006

Shaffer, D, Kizilisik, AT, Feurer, I, Nylander, WA, Helderman, JH, Langone, AJ, Schaefer, HM. Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications. Transplant Proc, 38(10), 3464-5, 2006

Schaefer, HM, Kaplan, B, Helderman, JH. Mortality after kidney transplantation: what lessons can we learn from regional and country variation. Am J Transplant, 6(1), 3-4, 2006

Schaefer, HM, Helderman, JH, Fogo, AB. Slow decline in allograft function in a renal transplant patient. Am J Kidney Dis, 48(2), 335-8, 2006

Tanriover, B, Chuang, P, Fishbach, B, Helderman, JH, Kizilisik, T, Nylander, W, Shaffer, D, Langone, AJ. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation, 80(2), 279-81, 2005

Ramanathan, V, Goral, S, Tanriover, B, Feurer, ID, Kazancioglu, R, Shaffer, D, Helderman, JH. Screening asymptomatic diabetic patients for coronary artery disease prior to renal transplantation. Transplantation, 79(10), 1453-8, 2005

Revelo, MP, Federspiel, C, Helderman, H, Fogo, AB. Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma. Nephrol Dial Transplant, 20(12), 2812-9, 2005

Johnston, A, Belitsky, P, Frei, U, Horvath, J, Hoyer, P, Helderman, JH, Oellerich, M, Pollard, S, Riad, H, Rigotti, P, Keown, P, Nashan, B. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. Eur J Clin Pharmacol, 60(6), 389-95, 2004

Halloran, PF, Langone, AJ, Helderman, JH, Kaplan, B. Assessing long-term nephron loss: is it time to kick the CAN grading system. Am J Transplant, 4(11), 1729-30, 2004

Langone, AJ, Helderman, JH. Experience with cyclosporine. Transplant Proc, 36(2 Suppl), 59S-63S, 2004

Kizilisik, AT, Ray, JM, Nylander, WA, Langone, AJ, Helderman, JH, Shaffer, D. Living donor kidney transplantation in a Veterans Administration medical center. Am J Surg, 188(5), 611-3, 2004

Kizilisik, AT, Ray, JB, Nylander, WA, Langone, AJ, Helderman, JH, Shaffer, D. Kidney transplantation in a veterans administration medical center: 40 years'' experience. Exp Clin Transplant, 2(2), 238-41, 2004

Shaffer, D, Langone, A, Nylander, WA, Goral, S, Kizilisik, AT, Helderman, JH. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant, 17 Suppl 9, 31-4, 2003

Helderman, JH, Bennett, WM, Cibrik, DM, Kaufman, DB, Klein, A, Takemoto, SK. Immunosuppression: practice and trends. Am J Transplant, 3 Suppl 4, 41-52, 2003

Kizilisik, AT, Feurer, ID, VanBuren, DH, Wise, P, Van Buren, D, Hopkins, J, Ray, J, Nylander, W, Shaffer, D, Helderman, JH, Langone, AJ, Speroff, T, Pinson, CW. Effects of diabetes and cadaveric organs on functional performance and health-related quality of life after kidney transplantation. Am J Surg, 186(5), 535-9, 2003

Geiger, X, Chang, I, Goral, S, Helderman, JH, Fogo, A. A 50-year-old man with persistent renal allograft dysfunction. Am J Kidney Dis, 40(1), 210-7, 2002

Helderman, JH, Goral, S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol, 13(1), 277-87, 2002

Kazancioglu, R, Goral, S, Shockley, SL, Feurer, ID, Ramanathan, V, Helderman, JH, VanBuren, D. A systematic examination of estimates of cyclosporine area under the curve in renal transplant recipients. Transplantation, 73(2), 301-2, 2002

Helderman, JH. General considerations of immunosuppressive therapies--efficacy versus toxicity. Transplant Proc, 33(3A Suppl), 2S-3S, 2001

Helderman, JH. Prophylaxis and treatment of gastrointestinal complications following transplantation. Clin Transplant, 15 Suppl 4, 29-35, 2001

Goral, S. and Helderman, J.H. Renal transplantation: approaches to graft dysfunction and the consequences of immunosuppression . Caring for the Renal Patient, Third Edition. Levine ed, 323-332, 1997

Helderman, J.H. and Goral, S. Update in transplantation 1995. Clinical Transplants 1995, Cecka and Terasaki, Eds. UCLA Tissue Typing Laboratory. (UCLA Press), 323-350, 1996

Helderman, J.H. and Goral, S. Transplantation immunobiology. Handbook of Kidney Transplantation, Second Edition. Danovitch,GM., ed. Little & Brown, Boston, MA , 14-31, 1996

Helderman, J.H., Van Buren, D.H., Amend, J.C., Jr., and Pirsch, J.D. Chronic immunosuppression of the renal transplant patient. J Amer Society of Nephrology , 4, S2-S9, 1994

Helderman, J.H. Principles and practices of renal transplant rejection. The Principles and Practices of Nephrology, , 811-821, 1994

Helderman, J.H., Womble, D., Ghandour, E., and Womble, S. Identification of a nonocyte-derived factor which regulates synthesis of insulin receptors on activated T-lymphocytes (MIRRF). Cytokine, 4, 528-536, 1992

Lipman, M.L., Stevens, A.C., Bleackley, R.C., Helderman, J.H., et al. The strong correlation of cytotoxic T lymphocyte-specific serine protease gene transcripts with renal allograft rejection. Transplantation, 53, 73-79, 1992

Mellema, J, Holterman, HJ, Waterman, HA, Blom, C, Gravenmade, EJ. Rheological aspects of mucin-containing solutions and saliva substitutes. Biorheology, 29(2-3), 231-49, 1992

Koffler, M., Raskin, P., Womble, D., and Helderman, J.H. Immunobiological consequence of regulation of insulin receptor on alloactivated lymphocytes in normal and obese subjects. Diabetes, 40, 364-370, 1991

Waterman, HA, Blom, C, Holterman, HJ, ''s-Gravenmade, EJ, Mellema, J. Rheological properties of human saliva. Arch Oral Biol, 33(8), 589-96, 1988

Helderman, J.H., et al. Confirmation of the utility of fine needle aspiration biopsy of the renal allograft. Kidney Int , 34, 376-381, 1988

Helderman, J.H., Ayuso, R., Rosenstock, J., and Raskin, P. Monocyte-T lymphocyte interaction for regulation of insulin receptors on the activated T lymphocyte. J Clin Invest , 79, 566-571, 1987